Q2 EPS Estimate for Enliven Therapeutics Lowered by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of Enliven Therapeutics in a report issued on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.60) per share for the quarter, down from their previous forecast of ($0.53). HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics' Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.45) EPS and FY2026 earnings at ($2.81) EPS.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06).

Separately, Jones Trading cut their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $37.25.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $0.37 during midday trading on Monday, hitting $16.40. The company's stock had a trading volume of 222,508 shares, compared to its average volume of 259,466. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm's 50 day moving average is $18.54 and its 200-day moving average is $21.44. The firm has a market cap of $804.73 million, a P/E ratio of -8.63 and a beta of 1.07.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $265,330. This trade represents a 20.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $16.49, for a total transaction of $82,450.00. Following the sale, the chief executive officer now owns 972,892 shares in the company, valued at approximately $16,042,989.08. This represents a 0.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,111 shares of company stock valued at $1,657,145 in the last 90 days. 29.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of ELVN. Franklin Resources Inc. acquired a new stake in Enliven Therapeutics in the third quarter valued at approximately $559,000. SG Americas Securities LLC grew its stake in Enliven Therapeutics by 66.1% in the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company's stock valued at $374,000 after acquiring an additional 6,616 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after acquiring an additional 1,275 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Enliven Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after acquiring an additional 6,611 shares during the period. Finally, Swiss National Bank grew its stake in Enliven Therapeutics by 13.9% in the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after acquiring an additional 5,100 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.